Donald L. Siegel, MD, PhD

faculty photo
Professor of Pathology and Laboratory Medicine at the Hospital of the University of Pennsylvania
Department: Pathology and Laboratory Medicine

Contact information
9-112 South Tower, Big 421
3400 Civic Center Blvd
Philadelphia, PA 19104
Office: (215) 662-3942
Lab: (215) 898-9655
Sc.B. (Biophysics)
Brown University, 1977.
Ph.D. (Biophysics)
Harvard University, 1983.
University of Pennsylvania, 1987.
Permanent link
> Perelman School of Medicine   > Faculty   > Details

Description of Research Expertise

Research Interests

Discovery and characterization of diagnostic and therapeutic monoclonal antibodies

Research Summary

My laboratory studies human immune repertoires in health and disease using phage display technologies for the production of human and non-human monoclonal antibodies relevant to transfusion medicine, benign hematology, infectious diseases, and oncology. Current studies focus on developing targeted drug delivery methods using red cell antibodies coupled to novel anti-thrombotic/anti-inflammatory molecules; cloning monoclonal primate neutralizing Dengue, Ebola, MERS and Zika virus antibodies for human in vivo antibody gene expression therapy; and isolating recombinant human and humanized antibody fragments for the design of T-cell chimeric antigen receptors for cancer therapy.

Description of Clinical Expertise

transfusion medicine, blood banking, apheresis, hematopoietic stem cell collection/processing, cGMP manufacture of cellular therapies for phase I first-in-human clinical trials

Selected Publications

70. Tebas, P., Jadlowsky, J.K., Shaw, P.A., Tian, L., Esparza, E., Brennan, A., Kim, S., Naing, S.Y., Richardson, M.W., Vogel, A.N., Maldini, C., Kong, H., Liu, X., Lacey, S.F., Bauer, A.M., Mampe, F., Lee, G., Dale Ando, D., Levine, B.D., Porter, D.L., Zhao, Y., Siegel, D.L., Bar, K.J., June, C.H., Riley, J.L.: CCR5-edited CD4 T cells augment HIV-specific immunity to enable post rebound control of HIV replication. J. Clin. Invest. Page: in press, 2021.

hoj, V., Li,, L., Parvathaneni, K., Zhang, Z., Kacir, S., Arhontoulis, D., Zhou, K., McGettigan-Croce, B., Nunez-Cruz, S., Gulendran,, G., Boesteanu, A.C., Johnson, L., Feldman, M.D., Radaelli, E., Mansfield, K., Nasrallah, M., Goydel,, R., Peng, H., Rader, C., Milone, M.C., Siegel, D.L.: Adoptive T cell immunotherapy for medullary thyroid carcinoma targeting GDNF family receptor alpha 4 (GFRa4). Molecular Therapeutic – Oncolytics in press, 2021.

Nobles, C., Sherrill-Mix, S., Everett, J.K., Reddy, S., Fraietta, J., Porter, D., Frey, N., Gill, S.I., Grupp, S., Maude, S., Siegel, D.L., Levine, B.L. June, C.H., Lacey, S., Melenhorst, J., Bushman, F.: Linking CART19 immunotherapy outcome with genomic modification by vector integration. J Clin Invest 130: 673-685, 2020.

61. He, X., Feng, Z., Ma, J., Ling, S., Cao, Y., Gurung, B., Wu, Y., Katona, B.W., O’Dwyer, K., Siegel, D.L., June, C.H., Hua, X.: Bi-specific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia. Blood 135: 713-723, 2020.

Stadtmauer, E.A., Fraietta, J.A., Davis, M.M., Cohen, A.D., Weber, K.L., Lancaster, E., Mangan, P.A., Kulikovskaya, I., Gupta, M., Chen, F., Tian, L., Gonzalez, V.E., Xu, J., Jung, I.Y., Melenhorst, J.J., Plesa, G., Shea, J., Matlawski, T., Cervini, A., Gaymon, A.L., Desjardins, S., Lamontagne, A., Salas-Mckee, J., Fesnak, A., Siegel, D.L., Levine, B.L., Jadlowsky, J.K., Young, R.M., Chew, A., Hwang, W.-T., Hexner, E.O., Carreno, B.M., Nobles, C.L., Bushman, F.D., Parker, K.R., Qi, Y., Satpathy, A.T., Chang, H.Y., Zhao, Y., Lacey, S.F., June, C.H: CRISPR-engineered T cells in patients with refractory cancer. Science 367: eaba7365, 2020.

Diorio, C., Shaw, P., Pequignot, E., Orlenko, A., Chen, F., Aplenc, R., Barrett, D.M., Bassiri, H., Edward Behrens, E., Gonzalez, V., Koterba, N., Levine, B.L., Maude, S.L., Meyer, N.J., Moore, J.H., Paessler, M., Porter, D.L., Rush, J., Siegel, D.L., Suhoski, M., Zhang, D., June, C.H., Grupp, S.A., Melenhorst, J.J., Lacey, S.F., Weiss, S.L., Teachey, D.T.: Diagnostic biomarkers to differentiate sepsis from cytokine release syndrome in critically ill children. Blood Adv in press, 2020.

Choi, H., Kudchodkar, S.B., Reuschel, E.L., Asija, K., Borole, P., Agarwal, S., Van Gorder, L., Reed, C.C., Gulendram, G., Ramos, S., Broderick, K.E., Kim, J.J., Ugen, K.E., Kobinger, G., Siegel, D.L., Weiner, D.B., Muthumani, K.: Synthetic nucleic acid antibody prophylaxis confers rapid and durable protective immunity against Zika virus challenge. Human Vaccines & Immunotherapeutics 16: 907-918, 2020.

Cohen, A., Garfall, A, Stadtmauer, E., Melenhorst, J., Lacey, S., Lancaster, E., Vogl, D., Weiss, B., Dengel, K., Nelson, A. M., Plesa, G., Chen, F., Davis, M., Hwang, W.-T., Young, R., Brogdon, J., Isaacs, R., Pruteanu-Malinici, I., Siegel, D. L., Levine, B., June, C. H., Milone, M.C.: B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. J Clin Invest 129: 2210-2221, 2019.

Chong, E.A., Levine, B.L., Gruppp, S.A., Davis, M.M., Siegel, D.L., Maude, S.L., Gladney, W.L., Frey, N.V., Porter, D.L., Hwang, W.-T., Chong, E.R., June, C.H., Schuster, S.J.: CAR T cell viability release testing and clinical outcomes: is there a lower limit? Blood 134: 1873-1875, 2019.

Gutjahr, A., Heck, F., Emtenani, S., Hammers, A.-K., Hundt, J.E., Muck, P., Siegel, D.L., Schmidt, E., Stanley, J.R., Zillikens, D., Hammers, C.M., Brit J Dermatol: Bullous pemphigoid autoantibody-mediated complement fixation is abolished by the low molecular-weight heparin tinzapatin sodium. Brit J Dermatol 181: 593-594, 2019.

back to top
Last updated: 02/20/2021
The Trustees of the University of Pennsylvania